Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2004-12-22
2008-10-07
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C435S235100, C435S320100
Reexamination Certificate
active
07431929
ABSTRACT:
The present invention relates to vaccines having an increased level of safety comprising recombinant vaccinia viruses containing an inactivated E3L region. The invention also relates to methods for stimulating a protective immune response in an immunized host using the vaccines of the invention. The invention is based on the discovery that vaccinia virus mutants having deletions in the E3L region exhibit dramatically reduced pathogenesis while remaining highly immunogenic. In addition, the invention relates to modified recombinant vaccinia viruses engineered to express heterologous polypeptides and the use of such viruses in vaccines designed to stimulate a protective immune response against such polypeptides in a host. The invention further relates to an interferon-sensitive recombinant vaccinia virus with broad host range wherein a salamander eIF2α is inserted into the viral genome in place of at least a portion of the E3L gene.
REFERENCES:
patent: 6004777 (1999-12-01), Tartaglia et al.
patent: 6372455 (2002-04-01), Jacobs et al.
patent: 6750043 (2004-06-01), Jacobs et al.
patent: 6846652 (2005-01-01), Jacobs et al.
patent: 6942855 (2005-09-01), Jacobs et al.
patent: 2002/0028195 (2002-03-01), Coffey et al.
patent: 2002/0155529 (2002-10-01), Jacobs et al.
patent: 2003/0044384 (2003-03-01), Roberts et al.
patent: WO 92/12240 (1992-07-01), None
patent: WO 9955910 (1999-11-01), None
patent: WO 00/00216 (2000-01-01), None
patent: WO 0062735 (2000-10-01), None
patent: WO 0073487 (2000-12-01), None
patent: WO 01/35970 (2001-05-01), None
patent: WO 02/086059 (2002-10-01), None
patent: WO 2004/003562 (2004-01-01), None
NCBI locus Q91S30. 2001. Obtained from the Internet Jul. 19, 2007 URL: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&id<81964299>.
Beattie et al. 1995. Reversal of the Interferon-Sensitive Phenotype of a Vaccinia Virus Lacking E3L by Expression of the Reovirus S4 Gene. J. Virol. 69(1):499-505.
Beattie et al., 2006. Host-range restriction of vasccinia virus E3L-specific deletion mutants. Virus Genes. 12(1):89-94.
Brandt TA, Jacobs BL. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol. Jan. 2001;75(2):850-6.
Chang et al. 1992. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, doubled-stranded RNA-dependent protein kinase. PBAS. 89 :4825-4829.
Chang et al. 1993. Identification of a Conserved Motif that is necessary for binding of the vaccinia virus E3L gene protucts to double-stranded RNA. Virology. 194:537-547.
Chang et al. 1995. Rescue of Vaccina Virus Lacking the E3L Gene by Mutants of E3L. J. Virol. 69(10):6605-6608.
Kibler et al., 1997. Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J. Virol. 71(3):1992-2003.
Langland JO, Cameron JM, Heck MC, Jancovich JK, Jacobs BL. Inhibition of PKR by RNA and DNA viruses. Virus Res. Jul. 2006:119(1):100-10.
McInnes et al. Orf Virus Encodes a Homolog of the Vaccinia Virus interferon-resistance gene E3L. Virus Genes 17(2):107-115.
Rosenthal et al. Developing New Smallpox Vaccines. Emerging Infectious Diseases vol. 7 No. 6, Nov.-Dec. 2001.
Shors et al. 1997. Complementation of vaccinia virus deleted of the E3L gene by mutants of E3L gene by mutants of E3L. Virology 239:269-276.
Vijaysri S, Talasela L, Mercer AA, Mcinnes CJ, Jacobs BL, Langland JO. The Orf virus E3L homologue is able to complement deletion of the vaccinia virus E3L gene in vitro but not in vivo. Virology. Sep. 15, 2003;314(1):305-14.
Xiang, Y, Condit RC, Vijaysri S, Jacobs B, Williams BR, Silverman RH. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol. May 2002;76(10):5251-9.
Xiang Y, et al. 2001. Vaccinia virus E3L suppresses the IFN system by preventing activation of antiviral enzymes and IRF3 phosphorylation. J. Interferon Cytokine Research. 24(s1)S70-S71.
Lee et al. “The Interferon-induced double stranded RNA-activated protein kinase induces apoptosis”Virology, vol. 199, pp. 491-196, 1994.
Jacobs Bertram
Jancovich James
Talasela Latha
Vijaysri Sangeetha
Arizona Board of Regents
Mosher Mary E
Womble Carlyle Sandrige & Rice PLLC
LandOfFree
Use of vaccinia virus deleted for the E3L gene as a vaccine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of vaccinia virus deleted for the E3L gene as a vaccine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vaccinia virus deleted for the E3L gene as a vaccine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4000239